|
| Merck & Co., Inc. and Subsidiaries |
|
|
|
|
Percentage Change
from Preceding Year |
Years Ended December 31
($ in millions except per share amounts) |
|
|
|
 |
| 2001 |
2000 |
1999 |
2001 |
2000 |
|
| Sales |
$47,715.7 |
$40,363.2 |
$32,714.0 |
+18% |
+23% |
| Research and development expenses |
2,456.4 |
2,343.8 |
2,068.3 |
|
|
| Net income |
7,281.8 |
6,821.7 |
5,890.5 |
+ 7% |
+16% |
| Earnings per common share assuming dilution |
$3.14 |
$2.90 |
$2.45 |
+ 8% |
+18% |
|
| Dividends paid per common share |
$1.37 |
$1.21 |
$1.10 |
+13% |
+10% |
Average common shares outstanding
assuming dilution (millions) |
2,322.3 |
2,353.2 |
2,404.6 |
|
|
|
| Total assets |
44,006.7 |
40,154.9 |
35,933.7 |
|
|
| Capital expenditures |
2,724.7 |
2,727.8 |
2,560.5 |
|
|
| Net income as a % of average total assets |
17.3% |
17.9% |
17.4% |
|
|
|
| Number of stockholders of record |
256,200 |
265,700 |
280,500 |
|
|
| Number of employees |
78,100 |
69,300 |
62,300 |
|
|
 |
 |
|
|
|
|
|
 |
(1) Amounts for 1994 include a full year’s impact on results of operations of the Medco acquisition and the impact of the formation of a joint venture with Astra in November 1994.
(2) Amounts for 1993 include the impact of the Medco acquisition and a restructuring charge. |
Trademarks: All product or service names appearing in type form different from that of the surrounding text are trademarks or service marks owned by or licensed to Merck & Co., Inc., its subsidiaries or affiliates. Cozaar and Hyzaar are registered trademarks of E.I. du Pont de Nemours and Company, Wilmington, Del., USA. Zetia is a registered trademark of Schering-Plough Corporation, Kenilworth, N.J., USA. Merck operates as MSD outside the United States.
|
|
|
